Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2012

View Archived Issues

Rexahn Pharmaceuticals obtains clearance for first-in-human RX-3117 study

Tesetaxel is active in patients with gastroesophageal cancer

Therapeutic investigation of dacomitinib expands to gastric cancer

MLN-8237 investigated with cisplatin in gastrointestinal cancer models

Alantos identifies potent disease-modifying candidate osteoarthritis drug

BrainStorm reports initial safety and efficacy data on NurOwn stem cell product

Vivalis and Sanofi Pasteur extend collaboration

Noscira completes randomization in tideglusib study

New Japanese approval of controlled-release paroxetine product

Trimel Pharmaceuticals advances phase III CompleoTRT study

Novelos Therapeutics starts phase Ib trial of radiotherapeutic agent in advanced solid tumors

Bristol-Myers Squibb patents novel chemokine CCR1 receptor ligands

Novel chemokine CCR2 receptor antagonists disclosed by Janssen

Chilean team presents new biomarker of gastric cancer progression

New insulin-like growth factor 1 receptor antagonists designed in Japan

FOB Synthesis claims new antibacterial agents

New PET imaging agents synthesized by Bracco Imaging

Trimesta studied in new phase II trial for cognitive dysfunction in MS

FDA clears clinical testing of oral epidermal growth factor receptor mutant-selective inhibitor

Hybrigenics files clinical trial application for inecalcitol in CLL

New JTE-013 analogues prepared in Italy

Ferrer cleared to begin phase III trials of ozenoxacin cream

Cell Therapeutics anticipates CHMP's opinion on Pixuvri MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...